Current Issue : January-March Volume : 2026 Issue Number : 1 Articles : 5 Articles
Drug resistance remains a major obstacle in cancer treatment despite advances in therapeutic regimens. To address this, we explored the potential of Doxorubicin (Dox) delivery in poly (lactide-co-glycolic acid) (PLGA) nanoparticles to enhance Diffuse large B-cell lymphoma (DLBCL) cell death. This research investigates the potential of Doxorubicin and advanced delivery methods. We used PLGA nanoparticles with Oleyl cysteineamide (OCA); its amphiphilic nature enables interfacial anchoring and thiol surface functionalization of PLGA NPs. Compared to PLGA-NPs, PLGA-OCA-NPs enhance immunity and induce tumor cell death. They also show significant apoptotic cell death and induced immune responses in DLBCL mouse models. Dox-conjugated PLGA-OCA-NPs (DOX-OCA) exhibit significant in vitro and in vivo anticancer activity compared to free DOX, showing remarkable antitumor effects with reduced systemic toxicity in mouse models. Our findings underscore the promising potential of PLGA-OCA-NPs in DLBCL treatment, offering a hopeful future in cancer therapy. This innovative delivery system offers enhanced immune responses and effectively addresses toxicity concerns, marking a significant step forward in cancer therapy....
Urinary catheters (UCs) are critical in biomedical applications, but prolonged use increases the risk of catheter-associated urinary tract infections (CAUTIs), a leading cause of healthcare-associated infections (HAIs). The present study presents a dual strategy to create an antibacterial surface on commercial Foley silicone UCs by combining a contact-killing effect with the controlled release of antimicrobial compounds. We designed a drug delivery system using a layer-by-layer (LbL) antibacterial coating of carboxymethylcellulose (CMC) and chitosan-silver (CHI-Ag) complexes, with ciprofloxacin (CFX) as the model drug. The resulting LbL coating, about 1 μm thick, incorporated Ag0 and demonstrated a high capacity for CFX loading, releasing over twice the amount (70 μg/cm2) compared to uncoated UCs (30 μg/cm2). The antibacterial efficacy was significantly higher in the LbL-coated samples, particularly against S. aureus compared to E. coli. Drug release experiments, modeled using Fick’s second law, indicated a diffusivity of 1.744 × 10−5 cm2/h. Our mathematical model predicts how variations in drug loading and rest times impact release profiles. Finally, molecular dynamics simulations suggested strong compatibility between CFX and the LbL layers, though with relatively low stability. This dual strategy holds promise for reducing CAUTIs effectively....
Microneedles represent an emerging transdermal drug delivery platform offering painless, minimally invasive penetration of the stratum corneum. This study addresses limitations of conventional lidocaine hydrochloride formulations, such as slow onset and poor patient compliance, by developing lidocaine hydrochloride-loaded dissolvable microneedles (LHDMNs) for rapid local anesthesia. LH-DMNs were fabricated via centrifugal casting using polyvinyl alcohol (PVA) as the matrix material in polydimethylsiloxane (PDMS) negative molds, which imparts high mechanical strength to the microneedles. Biocompatibility assessments showed negligible skin irritation, resolving within 3 min. And drug-loading capacity reached 24.0 ± 2.84 mg per patch. Pharmacodynamic evaluation via mouse hot plate tests demonstrated significant analgesia, increasing paw withdrawal latency to 36.11 ± 1.62 s at 5 min post-application (p < 0.01). The results demonstrated that the LHDMNs significantly elevated the pain threshold in mice within 5 min, surpassing the efficacy of conventional anesthetic gels and providing a rapid and effective solution for pain relief. These findings validate the system’s rapid drug release and efficacy, positioning dissolvable microneedles as a clinically viable alternative for enhanced transdermal anesthesia....
Spinal cord injury is a severe neurological condition that frequently. Results in lasting motor and sensory dysfunction. Traditional drug therapies have shown limited efficacy in addressing the complexities of spinal cord injury. This limitation highlighting the urgent need for innovative treatment strategies. In recent years, nanocarrier-mediated systems have garnered significant attention due to their superior drug delivery capabilities and targeting precision. This review summarizes the latest advancements in the application of nanocarriers for the treatment of spinal cord injuries, discussing various types of nanocarriers, drug loading and capacity and release profiles, as well as targeted delivery strategies. The insights aim to establish a theoretical foundation for future research and clinical applications in this critical area of medicine....
Introduction: Breast cancer treatment is plagued by systemic toxicity and drug resistance, prompting the search for better drug delivery systems, with oryzanol, a natural compound with anti-tumor potential but poor water solubility, emerging as a candidate. PLGA nanoparticles, a biodegradable and FDA-approved platform, are designed to encapsulate oryzanol, addressing its solubility issues and enabling targeted, controlled release to enhance anti-breast cancer efficacy. This study focuses on developing and characterizing γ-oryzanol-loaded PLGA (γ-oryzanol@ PLGA) nanoparticles, evaluating their formulation, cellular effects, and mechanisms, intending to lay a preclinical foundation for oryzanol as a safe adjuvant therapy for breast cancer. Methods: To address this unmet need, this study developed γ-oryzanol@PLGA nanoparticles (NPs) as a potential therapeutic strategy. Transmission electron microscopy (TEM) was used to characterize the morphology of the NPs. The colloidal stability and uniformity of nanoparticles were evaluated by measuring the polydispersity index (PDI) and zeta potential. Encapsulation efficiency and loading capacity were determined through UV-visible spectrophotometry. Flow cytometry was employed to assess the cellular uptake of the NPs compared to the free drug, and cytotoxicity assays were conducted to measure the effective concentration. Transcriptomic analysis was performed to identify differentially expressed genes and enriched cancer-related pathways. Results: TEM results showed that the NPs were spherical with uniform morphology, with blank NPs having a size of 232.50 ± 1.27 nm and drugloaded NPs being 241.60 ± 7.89 nm. The NPs exhibited excellent colloidal stability (PDI <0.03, zeta potential: −20 to −26 mV). Effective package load (86.22% ± 3.43%) and loading capacity (7.89% ± 0.31%) were achieved. Flow cytometry indicated a 3.2-fold enhanced cellular uptake compared to the free drug at 4 H (p < 0.05), and cytotoxicity assays showed a 3-fold reduction in the effective concentration. Transcriptomic analysis identified 576 differentially expressed genes and enriched cancer-related pathways, revealing the molecular mechanisms of the enhanced antitumor effects. Conclusion: Collectively, these findings demonstrate that γ-oryzanol@PLGA NPs significantly improve drug delivery efficiency and therapeutic potency while maintaining excellent biocompatibility. This presents a promising nanoplatform for breast cancer treatment, warranting further preclinical development. Future studies should focus on in vivo validation and the exploration of combination therapies to fully realize the potential of this novel approach....
Loading....